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Expression of Tie2/Tek in breast tumour vasculature
provides a new marker for evaluation of tumour
angiogenesis
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Summary Endothelial receptor tyrosine kinases may play important roles in pathological vascular growth, particularly in tumours. In this
study, immunohistochemistry was used to evaluate the expression of a novel endothelial receptor tyrosine kinase, Tie2/Tek, in the
endothelium of vascular 'hotspots' in normal breast tissue (n = 10), benign breast lesions (n = 10) and in breast tumours (n = 123). Tie2
expression was detected in the endothelium of all breast tissues examined. However, the strongest expression of Tie-2 was seen in vascular
'hot spots' within the inflammatory infiltrate at the periphery of invasive tumours. Moreover, the proportion of Tie2-positive vessels (Tie2
counts/CD31 counts) was significantly higher in breast tumours than the proportion of Tie2-positive vessels in either normal breast tissue or
benign breast lesions (P = 0.004 and 0.0001 respectively). These data are consistent with a role for Tie2 in tumour angiogenesis and
demonstrate the potential use of Tie2 expression as a novel marker of the tumour vasculature.
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It is now well established that the growth and development ofsolid
tumours is tightly linked to the development oftumour vasculature
(Craft et al, 1994; Hayes, 1994; Plate et al, 1994a; Folkman, 1995;
Rak et al, 1995). Consistent with this notion, a number of investi-
gators have demonstrated that quantitative estimates of tumour
vascularity are independent predictors ofprognosis in a variety of
solid tumours, most notably breast cancer (Weidner et al, 1991;
Bosari et al, 1992; Horak et al, 1992; Toi et al, 1993). Based on
studies such as these, a tremendous effort is being made to under-
stand the molecular mechanisms of tumour angiogenesis to
provide the basis for the development of novel diagnostic and
therapeutic agents.
Current evidence suggests that endothelial receptor tyrosine
kinases that mediate the effects of known 'angiogenic' growth
factors, such as VEGF (vascular endothelial growth factor) and
FGF (fibroblast growth factor) play crucial roles in physiological
and pathological vascular growth (Dvorak et al, 1991; Kim et al,
1993; Craft et al, 1994; Hayes, 1994; Plate et al, 1994a and b;
Senger et al, 1994; Brown et al, 1995; Folkman, 1995; Mustonen
et al, 1995; Rak et al, 1995; Takahashi et al, 1995; Millauer et al,
1996). Recently, a novel family of endothelium-specific receptor
tyrosine kinases currently consisting of two members, Tiel and
Tie2/Tek, has been shown to be essential for the normal develop-
ment of the embryonic vasculature (Dumont et al, 1992;
Maisonpierre et al, 1992; Partanen et al, 1992; Ziegler et al, 1992;
Sato et al, 1993). Disruption of Tiel function in transgenic mice
led to fetal or early post-natal lethality characterized by diffuse
vascular haemorrhage, suggesting a role for this receptor in
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maintaining vascular integrity (Puri et al, 1995; Sato et al, 1995).
Disrupting the function of Tie2, however, resulted in early
embryonic lethality characterized by a defect in the formation of
microvessels, supporting a role for Tie2 in developmental angio-
genesis (Dumont et al, 1994; Sato et al, 1995).
The requirement of Tiel and Tie2 function in the development
of the embryonic vasculature has led to speculation that they may
also play roles in normal and in pathological vascular growth in
adulthood. Consistent with this notion, Tiel mRNA was up-
regulated in the endothelium of the neovasculature of healing
skin wounds and in the endothelium of ovarian capillaries
after hormone-induced superovulation (Korhonen et al, 1992).
Moreover, Tiel expression has been shown to be up-regulated in
the neovasculature of a variety of cancers, including brain, breast
and melanoma, suggesting a role for Tiel in tumour angiogenesis
(Kaipainen et al, 1994; Hatva et al, 1995; Salven et al, 1996).
Whether Tie2 might be up-regulated in tumour vessels has not
been addressed. In the present study, a monoclonal antibody
against the Tie2 extracellular domain was used to demonstrate the
up-regulation of Tie2 expression in the pathological neovascula-
ture ofbreast tumours.
MATERIALS AND METHODS
Antibodies
A Tie2 murine monoclonal antibody was raised against purified,
recombinant human Tie2 extracellular domain. Details regarding
the production of this antibody will be described elsewhere (KG
Peters and P Rao, in preparation). Briefly, a recombinant protein
consisting of the entire human Tie2 extracellular domain fused at
its C-tail with a 6His tag was produced in insect cells using a
baculovirus expression system (Baculogold, Pharmingen). After
purification by Ni+NTA agarose chromatography, this protein was
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Table 1 Baseline characteristics of breast tissues examined by
immunohistochemistry
Diagnosis n Mean age (± s.e.) Node positive (%)a
Normal 10 45± 10 NA
Benign 10 32 ± 4 NA
Invasive ductal 104 53 + 2 56 (57/102)
Pure intraductal 5 54 ± 7 33 (1/3)
Loboular invasive 7 57 + 5 29 (2/7)
Recurrent cancer 2 47± 7 100 (2/2)
Medullary carcinoma 1 47 0 (0/1)
Cancer (not specified) 4 53 + 10 25 (3/4)
Total 143 52 ± 1.3 55 (65/119)
aNode status not known or not determined for all patients.
used to immunize mice for hybridoma production. Hybridoma
clones producing antibodies against the extracellular domain of
Tie2 were selected by Elisa using immobilized recombinant Tie2
as the target. The hybridoma clone producing the antibody (Ab 33;
IgGIK) that reacted best with the recombinant Tie2 extracellular
domain by Elisa was chosen for further evaluation by Western
blotting and immunohistochemistry. The CD31 antibody was a
murine monoclonal that was obtained from BioGenex.
Western blotting
Human umbilical vein endothelial cells (HUVECs) and human
aortic smooth muscle cells (HASMCs) were obtained from
Clonetics (San Diego) and grown in EGM media and SmGM
media respectively. HUVECs and HASMCs grown in six-well
plates were lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecyl sulphate (SDS) in 20 mm Tris-HCI
a1)
Cn
en
u1) 0c
C.)
200-
103-
97-
anti-Tie2 blot
Figure 1 Expression of Tie2 in cultured endothelial cells. Cell lysates from
HUVECs and HASMCs were prepared and probed with Ab33 as described in
Materials and methods. A single band of approximately 140 kDa was
recognized only in the endothelial lysates
pH 7.6, 150 mm sodium chloride, 50 mm sodium fluoride, 1 mM
sodium orthovanadate, 5 mm benzamidine and 1 mm EDTA
containing the protease inhibitors phenylmethylsulphonyl fluoride
(PMSF), aprotinin and leupeptin). Insoluble debris was removed
from the cell lysates by centrifugation at 14 000 g for 10 min at
Figure 2 Expression of Tie2 in breast tissues. Serial sections from benign breast tissues (A-D), or breast cancers (E-M) were immunostained using a control
anti-CD31 antibody (A, C, F, H) or an anti-Tie2 antibody (B, D, G, I, J-M). A-D and F-I show paired serial sections from four different tissue specimens stained
with the anti-CD31 antibody or the Tie2 antibody respectively. J-M show the expression of Tie2 in microvessels at the interface of the tumour (t) and the
peritumoral inflammatory infiltrate (i). E shows a negative control in which the primary antibody was deleted. Open arrows in J and L indicate microvessels in
the interface, which are depicted at higher magnification in K and M respectively. Magnification: A-G, J and L, x 200; H-I, x 150; K, x 900; M, x 600
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4°C, and 20,g of protein from HUVEC and HASMC cell lysate
was resolved by 8% PAGE and then electrotransferred to nitrocel-
lulose membrane and incubated with Ab33. Tie2 protein was visu-
alized by incubation ofthe membrane with HRP-linked secondary
antisera followed by treatment with enhanced chemiluminescence
(ECI) reagent (Amersham).
Immunohistochemistry
For immunohistochemistry, randomly chosen specimens snap-
frozen in OCT were obtained from archived material in the Duke
University Cancer Center Tumor Bank. Tumour specimens were
chosen to include about 50% node-positive and node-negative
cases. These tissues included ten normal breast specimens (from
reductive mammoplasties), ten benign lesions (fibroadenoma) and
123 tumours, the majority of which were invasive ductal carci-
nomas (Table 1). Serial sections from each specimen were post-
fixed in acetone for 10 min, air dried and incubated for 50 min
with either the Tie2 monoclonal antibody (Ab33) or the anti-
CD31 monoclonal antibody. For negative controls, the primary
antibody was deleted. Antigen antibody complexes were localized
using a commercially available HRP-based detection system
(Supersensitive, BioGenex).
Data analysis
To quantitate and compare Tie2 and CD31 expression, microvessels
expressing either antigen were counted, as previously described for
CD31 and other endothelial markers (Weidner et al, 1991; Horak et
al, 1992). Briefly, the most highly vascularized areas of each spec-
imen were identified by scanning the CD31-stained sections at low
power (x 40). Subsequently, individual microvessels expressing
CD31 were counted in three different high-power fields (x 400). As
the most prominent Tie2 staining colocalized with the most highly
vascularized regions (by CD31 staining), Tie2 expression was quan-
titated by counting Tie2-positive microvessels in the same regions
in which CD31 expression was determined. Microvessel number
was quantitated by two different investigators (KP and AC) without
consultation. Statistical analysis ofthe differences in overall tumour
vascularity (CD31 count) and Tie2 expression (Tie2 count) were
compared using t-tests.
RESULTS
To determine the expression pattern of Tie2 in breast tumours, a
murine monoclonal antibody was raised against a recombinant
extracellular domain of human Tie2 (see Materials and methods).
The hybridoma clones demonstrating the highest affinity for the
recombinant Tie2 by ELISA were selected for further evaluation.
Using Western analysis, one such clone, Ab33, recognized a single
band ofabout 140 kDa in lysates ofcultured human umbilical vein
endothelial cells (HUVECs), which are known to express endo-
genous Tie2 (Figure 1). In contrast, this band was not detected in
lysates from smooth muscle cells. Thus, Ab33 recognized an
endothelium-specific protein with a molecular mass consistent
with the Tie2 receptor tyrosine kinase.
Next, the expression of Tie2 was examined by immunohisto-
chemistry with Ab33 in tissue samples of normal human breast
tissue (n = 10), benign breast lesions (fibroadenoma; n = 10) and in
breast tumours (n = 123) (Table 1). To correlate Tie2 expression
with tumour vascularity, serial sections were stained in parallel
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Figure 3 Quantitation of Tie2 expression in normal breast tissue, benign
breast lesions and in breast cancers. Density of microvessels and expression
of Tie2 in 'vascular hot spots' were measured by counting vessels in 400 x
high-power fields of sections stained for CD31 or Tie-2 respectively. A shows
the comparison of Tie2 expression and B shows the comparison of
vascularity among normal breast tissues, benign breast lesions and breast
cancers. C compares the proportion of microvessels expressing Tie2
(expressed as the ratio of Tie2 to CD31 counts) in normal breast tissue,
benign breast lesions and breast cancers
with an anti-CD31 antibody (Horak et al, 1992; Toi et al, 1993). In
tumours, Tie2 was expressed most strongly in 'vascular hot spots',
identified by CD31 staining as areas of clustering of microvessels
(Figure 2E-I). Although vascular hot spots could often be detected
in the substance ofthe tumour, Tie2 expression was most intense in
areas of neovascularization at the tumour periphery, particularly in
the interface between the tumour and the characteristic peritumoral
inflammatory infiltrate (Figure 2J-M).
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Figure 4 Comparison of inter-observer variability of Tie2 counts and CD31 counts. The Tie2 counts (A) and CD31 counts (B) of two independent observers
were compared using linear regression analysis
In normal breast tissues, Tie2 was also expressed in vascular hot
spots, although the intensity of staining was generally lower than
that of Tie2 staining in tumours. In normal breast, hot spots were
typically localized around ductal structures (Figure 2C-D),
suggesting that Tie2 could play a role in the vascular proliferation
that occurs in concert with ductal hypertrophy during the
menstrual cycle. This possibility is currently being examined in a
prospective manner in clinical samples from reductive mammo-
plasty. Compared with normal breast tissues or breast cancers,
benign breast lesions (fibroadenomas) were typically less vascular,
had few if any vascular hot spots and tended to be subserved
by large ectatic vessels with little detectable Tie2 expression
(Figure 2A-B).
To quantitate expression of Tie2 in human breast tissues,
vascular hot spots were localized by low-power examination ofthe
stained tissue specimen, and the number of Tie2-positive vessels
was counted in individual high-power fields (x 400). Using this
approach, the number of Tie2-positive vessels in vascular hot
spots was significantly higher in tumours than in benign lesions or
normal breast tissue (Figure 3A). Quantitation of CD31-positive
vessels yielded similar results (Figure 3B). Similarly, vascular hot
spots in breast tumours had a significantly higher proportion of
Tie2-positive vessels (Tie2/CD31) than did benign breast lesions
or normal breast tissue (Figure 2C). Despite the increased expres-
sion ofTie2 in tumours, there was no statistically significant corre-
lation between Tie2 counts and tumour size, tumour grade or
lymph node status. Attesting to the reliability of counting Tie2-
positive vessels, the inter-observer variability of Tie2 counts
(Figure 4A) was similar to the inter-observer variability of
counting CD31-positive vessels (Figure 4B).
DISCUSSION
Applying an approach used for a number of other endothelial
markers, we have demonstrated that Tie2 expression represents a
new marker of breast tumour angiogenesis. Using immunohisto-
chemistry, Tie2 was expressed in the endothelium of most breast
tumours and was up-regulated compared with its expression in
either benign breast lesions or normal breast tissue. Somewhat
surprisingly, no statistically significant correlation between Tie2
expression and prognostic clinical variables could be found.
Nevertheless, these results are consistent with a role for Tie2 in the
development of the breast tumour vasculature and suggest that
antibodies against Tie2 could provide a useful adjunct to evalu-
ating the tumour vasculature.
Although most previous studies have demonstrated a direct
correlation between tumour vascularity and an adverse prognosis
in a variety of solid tumours, including breast cancer (Weidner et
al, 1991; Bosari et al, 1992; Horak etal, 1992; Weidner et al, 1992;
Fox et al, 1993, 1994; Toi et al, 1993; Gasparini et al, 1994;
Heimann et al, 1996), our study and other studies have not been
able to confirm these findings (Van Hoef et al, 1993; Axelsson et
al, 1995; Goulding et al, 1995; Siitonen et al, 1995). There are at
least two potential explanations for these disparate results. First,
immunostaining using endothelial markers, such as antibodies
against factor VIII-related antigen, CD34 and CD31, may be diffi-
cult to reproduce because of limitations of available methodology
for immunohistochemistry or, alternatively, because ofdifferences
in the methodology for selecting and quantitating vascular hot
spots (Van Hoef et al, 1993; Goulding et al, 1995). Second, it is
possible that simply quantitating the vascularity of individual
tumours may not always correlate with the ability ofthe tumour to
promote vascular growth. For example, it is likely that some
tumours, although highly vascular, have extremely limited abili-
ties to induce new vascular growth and thus may not differ prog-
nostically from poorly vascularized tumours with the same low
propensity to mediate new vessel growth.
Despite these disparate results, it seems likely that analysis of
the tumour vasculature will yield important prognostic and thera-
peutic information. For example, endothelial antigens that are up-
regulated during angiogenesis, such as VEGF receptors, have
already shown promise as markers of tumourendothelium in small
numbers of patients (Kaipainen et al, 1994; Senger et al, 1994;
Brown et al, 1995; Easty et al, 1995; Hatva et al, 1995; Rak et al,
1995; Takahashi et al, 1995). Interestingly, we were unable to
demonstrate a correlation between Tie2 expression and various
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prognostic indicators, including tumour size, tumour grade and
lymph node status. Our results are very similar to those obtained
by Salven and colleagues (1996) who found that despite the up-
regulation of Tiel in breast cancers compared with normal breast
tissue, there was no statistically significant correlation between
Tie1 expression and several prognostic indicators. As the proposed
role of the Tie family of receptors is in the maturation and stabi-
lization of nascent vessels, it is tempting to speculate that they
might not provide the earliest and therefore most sensitive markers
ofnewly formed vessels (Partanen et al, 1992; Dumont et al, 1994;
Puri et al, 1995; Sato et al, 1995; Folkman et al, 1996; Suri et al,
1996; Vikkula et al, 1996).
Vascular endothelial growth factor is currently a leading candi-
date for an endogenous mediator of tumour angiogenesis. VEGF
and VEGF receptors are expressed in the endothelium of a variety
of different tumours, and blocking VEGF receptors inhibit the
growth of a number of murine tumours and human tumour
xenografts (Dvorak et al, 1991; Millauer et al, 1994; Plate et al,
1994b; Senger et al, 1994; Brown et al, 1995; Easty et al, 1995;
Takahashi et al, 1995; Borgstrom et al, 1996). However, a recent
study showed that different murine mammary tumours had vari-
able responses after blockade of the VEGF pathway. Importantly,
tumours that did not respond well to VEGF blockade expressed
Tie2, suggesting that Tie2 could provide an alternative pathway for
tumour angiogenesis (Millauer et al, 1996). Taken together with
the results of the present study, these results are consistent with a
role for Tie2 in tumour angiogenesis and suggest that therapeutic
approaches targeting the Tie2 pathway should be further explored.
Considering this possibility, using a battery ofendothelial markers
may provide the best information for use both to determine
prognosis and perhaps to guide anti-angiogenic therapy.
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